Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer.
Authors: Chen WY; Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, 11031, Taiwan.; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan., Huang KH; Department of Surgery, Division of Urology, Chi-Mei Medical Center, Tainan, 710, Taiwan., Kajla G; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Wen YC; Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, 11031, Taiwan.; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.; TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei, 11031, Taiwan., Liu MK; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Fan YC; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Dung PVT; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Yeh HL; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Chen WH; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Jiang KC; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Li HR; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Chen CS; School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan., Huang J; Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA., Beltran H; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02215-5450, USA., Liu YN; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan. liuy@tmu.edu.tw.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan. liuy@tmu.edu.tw.; Prostate Center of Excellence, Taipei Medical University Hospital, Taipei Medical University, Taipei, 11031, Taiwan. liuy@tmu.edu.tw.; Taipei Medical University, 301, Yuantong Road, Zhonghe District, New Taipei City, 234, Taiwan. liuy@tmu.edu.tw.
Source: Cell communication and signaling : CCS [Cell Commun Signal] 2026 Jun 08. Date of Electronic Publication: 2026 Jun 08.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101170464 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-811X (Electronic) Linking ISSN: 1478811X NLM ISO Abbreviation: Cell Commun Signal Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1478-811X
DOI:10.1186/s12964-026-02977-y